Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

CVS Health : Enhancing the Specialty Management Model

share with twitter share with LinkedIn share with facebook
share via e-mail
06/12/2017 | 12:28pm CEST

Release date- 09062017 - Trip Hofer, Vice President of Product Development at CVS Specialty, recently spoke at the AHIP Institute and Expo on the unique challenges and opportunities of managing specialty drugs across pharmacy and medical benefits. Here, he discusses how we use technology to enhance payors' visibility and control of their specialty pharmacy claims, which can result in streamlined processes and better cost savings.

Managing specialty drugs is more complex than managing traditional prescription drugs, and it becomes even more challenging when some of these specialty drugs are paid for under the medical benefit, when claims are adjudicated and paid for the same way as medical services.

Consider the facts:

Nearly half of specialty spend is administered under the medical benefit.

This is expected to grow in the coming years as more than one-third of drugs currently in the specialty pipeline through 2018 will be managed under the medical benefit.

Infused specialty medications are estimated to account for $35 billion of the specialty market, and growing.

In addition, when drugs are managed under the medical benefit instead of the drug benefit it can complicate cost-saving utilization management programs, drive up spending and fragment patient care, not to mention create administrative burdens for the insurer and prescriber.

There is a better, more efficient way for insurers to streamline medical benefit management when it comes to specialty drugs, and at CVS Health, we are leading the way with the implementation of automated prior authorization and claims management for medical benefit specialty medications through a proprietary technology called Novologix.

Through our approach, we enable a seamless process that starts at the point of prescribing, where a web-based portal verifies patients' benefits and eligibility for certain medications. In addition, the technology integrates the prior authorization process and can also help identify clinically inappropriate dosing of medications and adjust the claims before adjudication. As part of this, we can also use the technology to help direct patients to the optimal and most cost effective site of care for infusion therapy.

This approach can produce results that include:

Savings of up to 19 percent for specialty drug medical spend;

$40 million in total savings in 2016 for a typical health plan covering one million lives from automated prior authorization;

Improved efficiency of prior authorization for providers, patients and the plan sponsor; and

Up to $7.5 million in savings when insurers help guide members away from more expensive hospital outpatient sites to alternate sites for high quality infusion care.

For more information on how CVS Health is working to ensure consumers have access to affordable medications, visit our Rising Drug Prices information center. And to stay informed about the most talked-about topics in health care, register for content alerts and our bi-weekly health care newsletter.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH
10/20 CVS HEALTH : Dividend Coverage: This Pharmacy Company has a Dividend Yield of 2...
10/19 CVS HEALTH : SilverScript Insurance Company, a CVS Health Company, Introduces Ne..
10/19 EXPRESS SCRIPTS : Anthem will turn to CVS for prescriptions
10/19 EXPRESS SCRIPTS : Anthem to turn to CVS after troubled deal
10/19DJAnthem To Launch Pharmacy Benefit Manager -- WSJ
10/18DJAnthem to Launch Its Own Pharmacy-Benefit Manager--3rd Update
10/18DJAnthem to Launch Its Own Pharmacy-Benefit Manager--2nd Update
10/18 MARKETS RIGHT NOW : US stocks closing higher; IBM surges
10/18 Anthem will turn to CVS after troubled Express Scripts deal
10/18DJAnthem to Launch Its Own Pharmacy-Benefit Manager--2nd Update
More news
News from SeekingAlpha
10/19 Dividend Growth Stocks Going Ex-Div October 23th-27th
10/19 Stocks Going Ex-Dividend The Fourth Week Of October
10/18 PHARMACY BEARS : High On Drugs
10/18 CVS Health inks five-year deal with Anthem to support PBM unit; shares up 2% ..
10/17 A REAL DIVIDEND GROWTH MACHINE : Q3 2017 Portfolio Review
Financials ($)
Sales 2017 184 B
EBIT 2017 10 051 M
Net income 2017 5 266 M
Debt 2017 24 750 M
Yield 2017 2,61%
P/E ratio 2017 14,75
P/E ratio 2018 12,82
EV / Sales 2017 0,55x
EV / Sales 2018 0,52x
Capitalization 75 866 M
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 86,7 $
Spread / Average Target 16%
EPS Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-5.42%75 327